Detroit, MI Clinical Trials Report — June 2026

For Detroit residents considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for trials nearing their enrollment deadlines. Across Detroit, MI, a total of 764 clinical trials are currently recruiting across 206 research facilities, offering diverse avenues for contributing to medical advancements.

A significant 46 trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Primary peritoneal cancer (3 trials)
• Solid tumor (2 trials)
• Advanced solid tumor (2 trials)
• Head and neck cancer (2 trials)
• Ovarian cancer (2 trials)
• Prostate cancer (2 trials)
• Endometrial cancer (2 trials)
• Breast cancer (2 trials)
• AML (2 trials)
• Fallopian tube cancer (2 trials)

New Research Opportunities Emerge in Detroit

This month, Detroit saw the opening of 7 new clinical trials, a positive increase from the 4 trials that launched in May 2026. This rebound indicates a renewed pace of research initiation in the city, following a trend that has seen between 7 and 9 new trials open each month since January.

June brings several high-profile new trials to Detroit, including significant Phase 2 drug studies from major pharmaceutical sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Bayer is initiating a notable Phase 2 study, NCT07625215, "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation." This study aims for 360 participants to evaluate the efficacy, safety, tolerability, and pharmacokinetics of BAY 3670549 compared to a placebo in individuals with atrial fibrillation who require electrical cardioversion.
• AstraZeneca is sponsoring NCT07652658, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in 359 participants with Idiopathic Pulmonary Fibrosis (IPF), including those already on antifibrotic therapy or those not receiving it.
• Indiana University is leading NCT07676565, "Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study," seeking 300 participants. This multicenter registry-based study will evaluate the safety and efficacy of GLP-1RA and SGLTi therapies used as adjuncts to insulin in adults with Type 1 Diabetes (T1D) over 1 year, enrolling participants prescribed these therapies as part of usual care.

New trials this month are exploring a range of conditions, including arthroplasty, replacement, hip, atrial fibrillation, defibrillators, fatty liver, heart arrest (out-of-hospital), idiopathic pulmonary fibrosis (IPF), MASLD, triple negative breast cancer, and type 1 diabetes. Drug trials account for the largest share of new studies, with 3 new drug trials, followed by 3 'OTHER' type trials, 2 behavioral studies, and 1 device trial.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. While 0 of the 7 new trials launched this month are actively seeking healthy volunteers, Detroit currently has a total of 41 clinical trials recruiting healthy participants. As mentioned, 7 of these healthy volunteer trials are closing within 90 days, making prompt inquiry beneficial.

Detroit's Leading Research Facilities

Detroit is home to prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Henry Ford Hospital (142 trials)
• Karmanos Cancer Institute (88 trials)
• Henry Ford Health System (80 trials)
• Henry Ford Health (47 trials)
• Henry Ford Health Saint John Hospital (45 trials)
• Wayne State University/Karmanos Cancer Institute (43 trials)
• Research Site (41 trials)
• Children's Hospital of Michigan (39 trials)
• Barbara Ann Karmanos Cancer Institute (23 trials)
• Wayne State University (21 trials)
• Henry Ford Cancer Institute (13 trials)
• John D. Dingell VA Medical Center, Detroit, MI (9 trials)

The Henry Ford Health System and its affiliated hospitals, along with the Karmanos Cancer Institute and Wayne State University, are clearly the most active research hubs in the city, offering a broad spectrum of studies, particularly in cancer research and general health. Henry Ford Health System itself sponsored 2 of the new trials this month.

Expanding Your Search: Beyond Detroit

While Detroit offers a substantial array of clinical trial opportunities, individuals may also find options in nearby communities within Michigan. Cities with active trials include Ann Arbor (18 trials), Bay City (2 trials), Southfield (2 trials), Bingham Farms (2 trials), Grand Rapids (2 trials), Ypsilanti (1 trial), Livonia (1 trial), and Royal Oak (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 7 new trials launched this month, 7 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is female-only, while 0 include children or are male-only. Academic institutions and healthcare systems continue to play a vital role in Detroit's research ecosystem, with Henry Ford Health System, Barbara Ann Karmanos Cancer Institute, Indiana University, and Wayne State University sponsoring new studies, alongside industry leaders like AstraZeneca and Bayer.

As June progresses, Detroit's research community continues to advance medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare, particularly for those ready to act on trials with impending deadlines.